Dynavax Technologies Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Dynavax Technologies stock.
View analyst ratings for Dynavax Technologies or view top-rated stocks.

Wall Street analysts have given Dynavax Technologies a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dynavax Technologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Dynavax Technologies.

Dynavax Technologies Co. (NASDAQ:DVAX) posted its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.02) by $0.03. The biopharmaceutical company had revenue of $83.34 million for the quarter, compared to analyst estimates of $60.42 million. Dynavax Technologies had a negative trailing twelve-month return on equity of 50.48% and a negative net margin of 51.91%.
View Dynavax Technologies' earnings history.

Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DVAX shares have increased by 201.3% and is now trading at $9.25.
View which stocks have been most impacted by COVID-19.

2 analysts have issued twelve-month price objectives for Dynavax Technologies' stock. Their forecasts range from $15.00 to $15.00. On average, they expect Dynavax Technologies' share price to reach $15.00 in the next year. This suggests a possible upside of 62.2% from the stock's current price.
View analysts' price targets for Dynavax Technologies or view top-rated stocks among Wall Street analysts.

13 employees have rated Dynavax Technologies CEO Eddie Gray on Glassdoor.com. Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and United Therapeutics (UTHR).
View all of DVAX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA).

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

Dynavax Technologies' stock is owned by a variety of institutional and retail investors. Top institutional investors include Federated Hermes Inc. (11.00%), BlackRock Inc. (7.47%), Chicago Capital LLC (5.11%), Blair William & Co. IL (1.98%), Geode Capital Management LLC (1.48%) and Rock Springs Capital Management LP (1.45%). Company insiders that own Dynavax Technologies stock include Andrew A F Hack, David F Novack, Francis Cano, Justin Burgess and Robert Janssen.
View institutional ownership trends for Dynavax Technologies.

DVAX stock was sold by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Edmond DE Rothschild Holding S.A., Redmile Group LLC, Credit Suisse AG, Northern Trust Corp, Victory Capital Management Inc., Jackson Square Capital LLC, and Price T Rowe Associates Inc. MD. Company insiders that have sold Dynavax Technologies company stock in the last year include David F Novack, Justin Burgess, and Robert Janssen.
View insider buying and selling activity for Dynavax Technologies or view top insider-selling stocks.

DVAX stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Federated Hermes Inc., D. E. Shaw & Co. Inc., BlackRock Inc., Citigroup Inc., Barclays PLC, Rafferty Asset Management LLC, and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have bought Dynavax Technologies stock in the last two years include Andrew A F Hack, and Francis Cano.
View insider buying and selling activity for Dynavax Technologies or or view top insider-buying stocks.

Shares of DVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DVAX stock can currently be purchased for approximately $9.25.

Dynavax Technologies has a market capitalization of $1.06 billion and generates $46.55 million in revenue each year. The biopharmaceutical company earns $-75,240,000.00 in net income (profit) each year or ($0.61) on an earnings per share basis.

Dynavax Technologies employs 245 workers across the globe.

The official website for Dynavax Technologies is www.dynavax.com.

Dynavax Technologies is headquartered at 2100 Powell Street Suite 900, Emeryville CA, 94608.

Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]